January 8, 2018 11:59 AM EST
Pharma

Af­ter bumpy 2017, Cel­gene CEO says tak­ing risk is the on­ly way for­ward

Brittany Meiling

SAN FRAN­CIS­CO — Cel­gene’s CEO Mark Alles kicked off JPM this morn­ing re­as­sur­ing in­vestors that bets on new­ly-ac­quired as­sets will keep the com­pa­ny’s mo­men­tum …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times